The NIA-AA research ATN framework emphasizes the incorporation of biomarker measures of amyloid, tau, and neurodegeneration/neuronal injury, providing an opportunity to classify individuals across the AD spectrum [13]. The gene discussed is MAPT; the disease is Alzheimer disease.